Literature DB >> 20113152

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

Emmanouil Sinakos, Ioannis Dedes, Lavrentis Papalavrentios, Antonios Drevelegas, Evangelos Akriviadis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113152     DOI: 10.3109/00365521003628335

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


× No keyword cloud information.
  2 in total

1.  Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.

Authors:  Jean-François Dufour; Hanno Hoppe; Markus H Heim; Beat Helbling; Olivier Maurhofer; Zsolt Szucs-Farkas; Ralph Kickuth; Markus Borner; Daniel Candinas; Bettina Saar
Journal:  Oncologist       Date:  2010-10-29

2.  The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.

Authors:  Emmanouil Sinakos; Gennaro Selvaggi; Lavrentis Papalavrentios; Andreas Tzakis; Evangelos Akriviadis
Journal:  Ann Gastroenterol       Date:  2011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.